Insufficient to assess effects on health outcomes because of limited number or power of studies, large and unexplained inconsistency between higher-quality studies; important flaws in design or conduct, gaps in the chain of evidence
Or lack of information on important health outcomes
Strength of recommendation
Strength of recommendation
Strong:
Benefits clearly > risks and burden OR risks and burden clearly > benefits
Weak:
Benefits finely balanced with risks and burden
Insufficient:
Insufficient evidence to determine net benefits or risks
Continuous arrivals of new drugs on the market1
Older formulations unavailable in European formularies2
